| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | Plasmodium vivax Major blood-stage surface antigen Pv200 |
| | (a.a.61-460) |
| | Swiss-Prot #: | Q26194 |
| | Entry name: | Q26194_PLAVI |
| | Protein | Major blood-stage surface antigen Pv200 (Merozoite surface protein 1) |
| | (Pv200 protein) |
| | Gene names: | Pv200 (MSP1) (PVX_099980) |
| | Organism: | Plasmodium vivax |
| | Codon-optimized cDNA Clone |
| | Cat#: | RPL-0545 |
| | Description: | Applications:1. Codon-optimized cDNA sequence designed for recombinant |
| | protein production in both E.coli and Mammalian cell. The cDNA has been |
| | cloned into E.coli expression vector with 6x Histidine tag. 2. May be used as |
| | RNAi assistance to restore the loss-of-function. |
| | Tag: | A 6x histidine tag |
| | Formulation: | Liquid |
| | Storage: | -20° to -70° C. Avoid repeated freeze-thaw cycles. |
| | Recombinant Protein |
| | Cat#: | PL-0545 |
| | Source: | Recombinant protein derived from E.coli. Or Yeast |
| | Tag: | A 6x histidine tag |
| | Formulation: | Liquid |
| | Purity: | > 90%, as determined by SDS-PAGE under reducing conditions |
| | Activity: | N/A |
| | Applications: | Western Blot, may be used for other applications determined by |
| | Storage: | -20° to -70° C. Avoid repeated freeze-thaw cycles. |
| | Sequence: | | MKALLFLFSF IFFVTKCQCE TESYKQLVAK LDKLEALVVD GYELFHKKKL GENDIKVETN ASANNNNNNQ VSVLTSKIRN |
| | FLSKFLELQI PGHTDLLHLI RELAVEPNGI KYLVESYEEF NQLMHVINFH YDLLRAKLHD MCAHDYCKIP EHLKISDKEL |
| | DMLKKVVLGY RKPLDNIKDD IGKLETFITK NKITIKNISD LIIAENKKRS GHPTTTTNGA GTQPANGSIA AASSETTQIS |
| | GSSNSGSSST GSSNSGSSST GSSGTGSTGT GQSPPAAADA SSTNANYEAK KIIYQAVYNT IFYTNQLQEA QKLIAVLEKR |
| | VKVLKEHKDI KVLLEQVAKE KEKLPSDYPN TTNLTNVHKE AESKIAELEK KIEAIAKTVN FDLDGLFTDA EELEYYLREK |
| | AKMAGTLIIP ESTKSAGTPG KTVPTLKETY PHGISYALAE NSIYELIEKI GSDETFGDLQ NPDDGKQPKK GILINETKRK |
| | ELLEKIMNKI KIEEDKLPNL KKEYEEKYKV YEAKVNEFKP AFNHFYEARL DNTLVENKFD DFKKKREAYM EEKKKLESCS |
| | YEQNSNLINK LKKQLTYLED YVLRKDIADD EIKHFSFMEW KLKSEIYDLA QEIRKNENKL TIENKFDFSG VVELQVQKVL |
| | IIKKIEALKN VQNLLKNAKV KDDLYIPKVY KTSEKPEPYY LMVLKREIDK LKDFIPKIES MIATEKNKPT VAAADIVAKG |
| | QSLRGASETG TTGNTVNAQT AVVQPQHQVV NAVTVQPGTT GHQAQGGEAE TQTNSVQAAQ VQQTPAGAGG QVASTQTISQ |
| | APAPTQASPE PAPAAPPSTP AAAVAPAPTM SKLEYLEKLL DFLKSAYACH KHIFVTNSTM KKELLDQYKL NADEQNKINE |
| | TKCDELDLLF NVQNNLPAMY SIYDSMSNEL QNLYIELYQK EMVYNIYKNK DTDKKIKAFL ETLKSKAAAP AQSAAKPSGQ |
| | AGTTPVTTTA PVTTTTVTPS PQTSVVTSTP PTPQAEENRR VGGNSEEKPE ADTAQVEKFY EKHLSQIDKY NDYFQKFLES |
| | QKDEITKMDE TKWKALGAEI EELKKKLQVS LDHYGKYKLK LERLLKKKNK ISNSKDQIKK LTSLKNKLER RQNLLNNPTS |
| | VLKNYTAFFN KKRETEKKEV ENTLKNTEIL LKYYKARAKY YIGEPFPLKT LSEESMQKED NYLNLEKFRV LSRLEGRLGK |
| | NIELEKENIS YLSSGLHHVL TELKEIIKNK KYSGNDHTKN IAAVKEALQA YQELIPKVTT QEGASTTAAT LPVTVPSAVP |
| | GGLPGAGVPG AAAGLTPPPP AGSVPATGPG AAAGSTEENV AAKAQDYAED YDKVIALPLF GNNDDDGEED QVTTGEAESE |
| | APEILVPAGI SDYDVVYLKP LAGMYKTIKK QLENHVNAFN TNITDMLDSR LKKRNYFLEV LNSDLNPFKY SSSGEYIIKD |
| | PYKLLDLEKK KKLIGSYKYI GASIDMDLAT ANDGVTYYNK MGELYKTHLD GVKTEIKKVE DDIKKQDEEL KKLGNVNSQD |
| | SKKNEFIAKK AELEKYLPFL NSLQKEYESL VSKVNTYTDN LKKVINNCQL EKKEAEITVK KLQDYNKMDE KLEEYKKSEK |
| | For pricing and availability Click Here >>> |
| | Recombinant-Protein-blood-stage-surface-antigen-Pv200-Plasmodium |
| | FOR in vitro RESEARCH USE ONLY. NOT FOR USE IN HUMANS. |
|
| ||||||||||||||||||||||||||||||||||
| |||||
| For cDNA or Recombinant Protein Search (Input Cat#, Gene name, Protein Name, Accession Number |
|
Copyright Bioclone Inc All rights Reserved